par Lin, Nancy U;Diéras, Véronique;Paul, Devchand;Lossignol, Dominique 
;Christodoulou, Christos;Stemmler, Hans-Joachim;Roche, Henri;Liu, Cindy Meng Hsin;Greil, R.;Ciruelos, Eva;Loibl, Sibylle;Gori, Stefania;Wardley, Andrew;Yardley, Denise;Brufsky, Adam;Blum, J.;Rubin, Stephen D;Dharan, Bernie;Steplewski, Klaudia;Zembryki, Denise;Oliva, Cristina;Roychowdhury, Debasish;Paoletti, Paolo;Winer, Eric P
Référence Clinical cancer research, 15, 4, page (1452-1459)
Publication Publié, 2009-02
;Christodoulou, Christos;Stemmler, Hans-Joachim;Roche, Henri;Liu, Cindy Meng Hsin;Greil, R.;Ciruelos, Eva;Loibl, Sibylle;Gori, Stefania;Wardley, Andrew;Yardley, Denise;Brufsky, Adam;Blum, J.;Rubin, Stephen D;Dharan, Bernie;Steplewski, Klaudia;Zembryki, Denise;Oliva, Cristina;Roychowdhury, Debasish;Paoletti, Paolo;Winer, Eric PRéférence Clinical cancer research, 15, 4, page (1452-1459)
Publication Publié, 2009-02
Article révisé par les pairs
| Résumé : | Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical challenge. Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial. The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine. |
